Who is sponsoring NCT05248919?

NCT05248919 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT05248919?

Interventions in NCT05248919: Epclusa (nucleotide HCV NS5B polymerase inhibitors)..

What condition does NCT05248919 study?

NCT05248919 studies Hepatitis C.

Is NCT05248919 still recruiting?

NCT05248919 is currently enrolling by invitation. Last updated 20 November 2025.

Last reviewed 2025-11-20 · How we verify

NCT05248919

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan

ENROLLING BY INVITATION NA Last updated 20 November 2025

What this trial tests

NA trial testing Epclusa (nucleotide HCV NS5B polymerase inhibitors). in Hepatitis C in 318 participants. Enrolling by invitation.

Timeline

1 June 2023

Primary endpoint
1 September 2027

1 September 2027

Quick facts

Lead sponsor	Queen Mary University of London
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	318
Start date	1 June 2023
Primary completion	1 September 2027
Estimated completion	1 September 2027
Sites	1 location across Pakistan

Drugs / interventions tested

Epclusa (nucleotide HCV NS5B polymerase inhibitors). — full drug profile →

Conditions studied

Hepatitis C — all drugs for Hepatitis C →

Sponsor

Queen Mary University of London

Who can join

Adults 18 to 100, any sex, with Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Determine sustained virological response rate (SVR)
Time frame: 36+/- 2 weeks from the point of randomisation
Sustained virological response (SVR) defined as proportion of patients who are HCV RNA negative with a sensitive molecular test (sensitivity \<100 IU/ml) 36 +/- 2 weeks from the time of randomisation. 2\. To determine the proportion of people with decompensated cirrhosis who achieve a sustained virological response (SVR) 36 weeks (+/-2 weeks) after first dose of medication (sofosbuvir/velpatasvir

Sponsor's own description

This trial is linked to a largescale observational study determining the efficacy of sofosbuvir/daclatasvir in people in Pakistan (involving a separate protocol). The observational study will identify a cohort of patients who have not responded to first-line antiviral therapy (sofosbuvir plus daclatasvir) and the optimal treatment for these patients is unclear. This trial will address this issue by comparing two second-line treatment regimens to determine the preferred treatment option.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis C

Currently open trials in the same condition.

NCT06263829 — HCV Tappt Adherence Study · NA · recruiting
NCT06179498 — Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs · NA · recruiting
NCT06367465 — Feasibility and Acceptability of HCV Treatment in Pregnancy · recruiting
NCT05668780 — Buprenorphine Integration Research and Community Health · NA · active not recruiting
NCT05208697 — Tele-Harm Reduction · NA · active not recruiting

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05248919 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 20 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05248919.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing